Steigerwald Gordon & Koch Inc. Sells 953 Shares of Stryker Co. (NYSE:SYK)

Steigerwald Gordon & Koch Inc. trimmed its position in Stryker Co. (NYSE:SYK - Free Report) by 1.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 69,282 shares of the medical technology company's stock after selling 953 shares during the quarter. Stryker makes up approximately 2.8% of Steigerwald Gordon & Koch Inc.'s portfolio, making the stock its 8th biggest holding. Steigerwald Gordon & Koch Inc.'s holdings in Stryker were worth $24,945,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Dale Q Rice Investment Management Ltd purchased a new stake in Stryker in the fourth quarter valued at approximately $587,000. PFW Advisors LLC bought a new position in shares of Stryker in the fourth quarter worth approximately $1,350,000. Parnassus Investments LLC bought a new position in shares of Stryker in the third quarter worth approximately $762,798,000. Baltimore Washington Financial Advisors Inc. grew its holdings in shares of Stryker by 2.4% in the third quarter. Baltimore Washington Financial Advisors Inc. now owns 66,681 shares of the medical technology company's stock worth $24,089,000 after purchasing an additional 1,554 shares during the last quarter. Finally, Sivik Global Healthcare LLC grew its holdings in shares of Stryker by 8.0% in the third quarter. Sivik Global Healthcare LLC now owns 27,000 shares of the medical technology company's stock worth $9,754,000 after purchasing an additional 2,000 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Stryker

In other news, CEO Kevin Lobo sold 57,313 shares of the company's stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $368.70, for a total value of $21,131,303.10. Following the transaction, the chief executive officer now owns 100,027 shares of the company's stock, valued at $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 5.90% of the stock is owned by company insiders.

Stryker Stock Up 0.6 %

Shares of SYK stock traded up $2.12 during trading hours on Monday, reaching $383.91. 1,727,106 shares of the company's stock were exchanged, compared to its average volume of 1,070,245. Stryker Co. has a 1 year low of $307.23 and a 1 year high of $398.20. The stock has a market cap of $146.35 billion, a PE ratio of 41.15, a PEG ratio of 2.51 and a beta of 0.95. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The stock's fifty day moving average price is $375.51 and its two-hundred day moving average price is $359.17.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.77 by $0.10. The company had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. Stryker had a return on equity of 23.07% and a net margin of 16.34%. Stryker's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period in the previous year, the company posted $2.46 earnings per share. Research analysts predict that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a $0.84 dividend. This is a boost from Stryker's previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a yield of 0.88%. The ex-dividend date is Tuesday, December 31st. Stryker's dividend payout ratio is presently 36.01%.

Wall Street Analysts Forecast Growth

SYK has been the topic of several recent analyst reports. JPMorgan Chase & Co. raised their target price on shares of Stryker from $375.00 to $420.00 and gave the stock an "overweight" rating in a report on Wednesday, October 30th. Evercore ISI lifted their price target on shares of Stryker from $380.00 to $384.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. StockNews.com upgraded shares of Stryker from a "hold" rating to a "buy" rating in a report on Thursday, January 9th. Barclays lifted their price target on shares of Stryker from $402.00 to $418.00 and gave the company an "overweight" rating in a report on Thursday, October 31st. Finally, Robert W. Baird lifted their price target on shares of Stryker from $378.00 to $405.00 and gave the company an "outperform" rating in a report on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $405.80.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.